Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

AnHeart-Innovent Granted China Breakthrough Status for NSCLC Drug

publication date: Mar 1, 2022

AnHeart Therapeutics (Hangzhou) and Suzhou Innovent said their partnered ROS1 tyrosine kinase inhibitor received China Breakthrough Therapy Designation. In a China Phase II trial, taletrectinib posted a 90% response rate in ROS1 fusion-positive NSCLC patients who had not been previously treated. Taletrectinib is a novel next-gen ROS1 inhibitor that targets ROS1 fusion mutations with potential to treat both TKI-naïve and pre-treated patients. In 2021, Innovent signed a $189 million agreement with AnHeart for co-comercialization rights tor taletrectinib in Greater China. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.